CML is a slow-growing tumor, with patients appropriately treated with a tyrosine kinase inhibitor targeting BCR-ABL remaining in the chronic phase for many years. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.